Skip to content
Review Open access

The Role of Tumor-Associated Macrophages in Lung Cancer Progression and Therapy: From Mechanistic Insights to Targeting Strategies

Nov 2026 · Drug Design, Development and Therapy · Vol 20 · 0 citations · 90 references
Medicine

Abstract

Abstract Tumor-associated macrophages (TAMs) are among the most abundant immune cells in the lung cancer tumor microenvironment (TME), where their functions vary according to developmental origin, local signals, metabolic conditions, spatial location, and treatment exposure. The conventional M1 and M2 framework therefore does not adequately represent the diversity of macrophage states in human tumors. This narrative review examines the origin of TAMs in lung cancer, their context-dependent functional states, spatial organization, and interactions with current treatments in non-small cell lung cancer and small cell lung cancer. Single-cell RNA sequencing and spatial transcriptomics have identified macrophage populations associated with primary tumors and specific metastatic sites. Mechanistic studies further implicate cytokine signalling, extracellular vesicle communication, metabolic regulation, and phagocytosis checkpoints in tumor cell proliferation, stemness maintenance, epithelial-mesenchymal transition (EMT), angiogenesis and the formation of an immunosuppressive microenvironment. TAMs can contribute to tumor clearance in some settings but promote immune suppression, tissue repair, and treatment resistance in others. Targeting strategies directed against TAMs, including inhibition of monocyte recruitment, modification of tumor-supportive macrophage states, blockade of phagocytosis checkpoints, and macrophage-directed drug delivery, have demonstrated activity primarily in experimental lung cancer models. However, clinical studies have not yet established the efficacy, selectivity, or safety of these approaches. Major challenges remain, including the high heterogeneity of TAMs, activation of compensatory pathways, systemic toxicity, and the translational gap between preclinical and clinical studies. Future research should focus on validating markers that distinguish disease-associated macrophage states from macrophages required for pulmonary homeostasis and integrating longitudinal tissue, circulating, spatial, and imaging biomarkers. Controlled clinical studies are required to determine whether macrophage-directed interventions can improve existing lung cancer treatments.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.